News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shire Release: Firazyr®: First Subcutaneous Treatment For Acute Attacks Of Rare And Serious Swelling Disorder Now Available In Canada



7/21/2014 5:05:27 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONTRÉAL, July 17, 2014 /CNW/ - Shire Canada Inc. ("Shire") announced today the availability of FIRAZYR® (icatibant injection) in Canada for the treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase inhibitor deficiency. Firazyr is the first and only subcutaneous, ready-to-use option available to Canadians living with the rare and serious disorder.

Help employers find you! Check out all the jobs and post your resume.

Read at CNW


comments powered by Disqus
CNW
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES